BLASUBCUTANEOUSSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
RELEUKO (filgrastim) by Kashiv BioSciences. Approved for chemotherapy-induced neutropenia, neutropenia. First approved in 2022.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELEUKO is a subcutaneous filgrastim (granulocyte colony-stimulating factor) solution approved by FDA in February 2022 for chemotherapy-induced neutropenia and neutropenia. It stimulates neutrophil proliferation and differentiation by binding to G-CSF receptors on hematopoietic cells. This is a biosimilar or follow-on filgrastim product in a mature G-CSF market.
Peak
RELEUKO is in peak lifecycle as a relatively new market entrant competing in a saturated G-CSF market with 30% competitive pressure; expect modest team expansion focused on share-of-wallet capture.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications (2)
Clinical Trials (20)
Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia
Started Jan 2026
100 enrolled
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Started Apr 2025
18 enrolled
Preeclampsia
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Started Mar 2025
18 enrolled
Preeclampsia
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Started Nov 2023
100 enrolled
Breast Neoplasms
Worked on RELEUKO at Kashiv BioSciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.